Figure 8 | Scientific Reports

Figure 8

From: New Therapeutic Approach for Targeting Hippo Signalling Pathway

Figure 8

NLS18-TEAD has anti-tumoral effect on breast cancer xenograft models. (a) C3H/S-strain mice subcutaneously inoculated with 4 × 105 TN60-UNLP cells were intraperitoneally treated with 5 mg/kg of NLS18-TEAD or NLS23-TEAD 5 days per week for 4 weeks. Control mice received NaCl. Tumor growth was monitored each other day. The average tumor volume of each group (8 mice per group) is shown (p < 0.018). (b) The weight of the animals and the organs upon 30 days of treatment with the peptides NLS18-TEAD or NLS23-TEAD is shown. Control non-treated mice are also shown. p and t statistic values are shown.

Back to article page